The BioCalendar

ESC Congress 2026
2026-08-31 | Munich, Munich, Bavaria, Germany
Join us and experience transformation through practice, policy, responsibility and genuine human connection.
This year’s Spotlight on Artificial Intelligence explores how AI is becoming a co-pilot, enhancing precision, speed, and safety in patient care. Discover AI in action, from diagnosis to delivery, through hands-on sessions, live demonstrations, and immersive learning.
Here we will explore a diverse range of topics, uniting all subspecialties to create a space to share breakthrough data and debate new ideas, before applying innovation to real-world settings.
This is where collaboration becomes progress, and transformation is not just seen, but felt.

Outsourced Pharma Capabilities Update: CPHI Milan 2026 Special Edition
2026-08-27 10:00 - 11:00 (America/Los_Angeles)
Are you making the most of your time at CPHI Milan?
Watch this free virtual event to evaluate CDMOs, CMOs, API suppliers, packaging providers, and other outsourcing partners before you arrive onsite. Gain early insight into supplier capabilities, compare potential partners, and build a focused meeting strategy that maximizes your time at CPHI Milan.
Register today to identify the right partners, prioritize high-value conversations, and arrive in Milan ready to make informed outsourcing decisions.

Controlling UF/DF with Confidence: How to Define, Monitor, and Hit Critical Endpoints
2026-08-26 11:00 - 12:00 | Online webinar
A practical framework for reducing variability, minimizing manual sampling, and improving run-to-run consistency with modern UF/DF control strategies.
August 26, 2026 | 11:00 AM ET
Ultrafiltration Diafiltration (UF/DF) is often treated as a straightforward concentration and buffer-exchange step, but teams know the reality looks different. Small differences in setup, endpoint definition, and in-process decision-making can create major run-to-run variability, especially as programs move from process development into scale-up and manufacturing.
In this webinar, we will focus on the practical question that determines whether UF/DF is repeatable and scalable: How do you define the right endpoints, monitor them in real time, and consistently hit them without relying on constant manual sampling and operator intervention? We will walk through a clear approach to selecting critical UF/DF endpoints (for concentration and diafiltration), connecting them to the right measurements, and using in-line analytics to improve accuracy and consistency.
Key topics include:
What “critical endpoints” really mean in UF/DF, and why unclear endpoints drive variability across runs and teams
Endpoint selection made practical: choosing concentration and diafiltration endpoints that align with process goals and downstream requirements
How real-time, in-line concentration data enables automated control, reducing manual sampling and dilution while improving efficiency, consistency, and decision-making
Reducing variability across scales by linking endpoint definition, monitoring strategy, and execution consistency from PD through manufacturing
Troubleshooting through the lens of control: how clearer endpoints and better monitoring help teams respond faster to instability and performance drift
Whether you are building a UF/DF strategy in development, preparing for tech transfer, or tightening control in manufacturing, this session will provide practical guidance for making UF/DF easier to run, easier to scale, and easier to reproduce.

MEDevice Boston
2026-08-26 - 2026-08-27 | Boston, MA, 02210, United States
MEDevice Boston, by Informa, brings together leading medical device OEMs, startups, and suppliers from New England and beyond into a MedTech event engineered to advance the industry.
Intentionally designed for partner connections and supplier evaluation, this two-day experience creates a focused environment where high-intent buyers and solution providers connect. Through curated networking, hands-on learning, and dynamic on-site features, MEDevice Boston drives meaningful conversations, strategic partnerships, and the technologies shaping the next generation of medical devices.

Driving Measurable Productivity Gains in CHO Cell Culture
2026-08-25 11:00 - 12:00
Achieving consistent upstream performance remains a critical challenge as bioprocesses become more complex and quality expectations continue to rise. From variability in raw materials to maintaining cell growth, productivity, and product quality across platforms, process developers are under increasing pressure to build more robust and reliable manufacturing processes.
Join this webinar to explore practical strategies for optimizing upstream CHO cell culture performance through media component selection and process design. Through real-world application data and case studies spanning both monoclonal antibodies and emerging antibody modalities, our experts will share insights into reducing variability, improving process consistency, and enhancing key cell culture outcomes.
Learning Objectives:
~ Understand the impact raw material variability can have on upstream process performance and product quality
~ Explore approaches to improving consistency, cell growth, viability, and productivity in CHO-based processes
~ Review case studies demonstrating successful media optimization strategies across multiple antibody production workflows
~ Gain practical insights to support media selection and upstream process development decisions

Next Generation Dx Summit
2026-08-24 - 2026-08-26 | Washington, DC, Washington, DC, United States
Breakthrough Tech. Expert Insights. Real-World Impact.

400+ diagnostics professionals from across the industry
120+ speakers leading innovation in clinical and molecular Dx
6 highly focused tracks spanning emerging technologies and commercial strategy
Unmatched networking with partners, labs, regulators, and investors
Emerging company spotlight with novel platform technologies

Next Generation Dx Summit is where the diagnostics ecosystem converges to accelerate innovation and expand patient access

Gain the latest insights in:

Clinical implementation and validation of diagnostic technologies
Point-of-care innovation and at-home testing
Early detection and enhanced screening of single cancers and MCEDs
AI, digital, and emerging applications in companion diagnostics
AI in lab management, testing, clinical decision support, and analysis

Container Closure Integrity Testing: Selecting a Test Method for your Container System
2026-08-21 11:00 - 12:00
Join us for a practical discussion on selecting the right Container Closure Integrity Testing (CCIT) method for your container system. Learn how deterministic and probabilistic approaches compare, understand the impact of package design and product characteristics on method selection, and gain a risk-based framework for justifying your CCIT strategy to regulators.

BVS’ Biotech Community Event at One Alexandria Square, San Diego
2026-08-20 11:00 - 13:30 | San Diego, San Diego, CA, United States
We are very excited to announce our outdoor Biotech Community Event in the Tribute Garden at One Alexandria Square.
Mark your calendars for a great opportunity to connect with industry leaders, explore innovative products, and mingle with fellow professionals in the biotech community.
✨ What to Expect:
Vendor Exhibits: Discover a diverse range of exhibitors showcasing cutting-edge technology and services in the biotech space.
Networking Opportunities: Engage with fellow industry experts, forge new connections, and exchange ideas that could shape the future of biotech.
Delicious Lunch & Drinks: Enjoy a delicious lunch as you network and explore the vendor exhibits.
We are inviting all the tenants and all local life science researchers and entrepreneurs in the surrounding area to attend.
Admission Details:
FREE for life science job-related employees (including researchers, scientists, purchasing, clinical, manufacturing, non-sales/bus dev positions etc.) from life science companies and research institutes.
$200 fee for product and service providers who sell to the life science community (e.g. BVS suppliers, business development/sales, marketing, lawyers, consultants), which includes access to the event but does not include an exhibitor table. Exhibitor tables can be purchased separately.
For exhibitor tables, please visit our website and register at: https://bvsconnection.com/events
Please feel free to invite others in the community that could benefit from attending.
We look forward to seeing you there!

Where Precision Drives Progress: Meeting the Rising Complexity of Modern Clinical Trials
2026-08-20 11:00 - 12:00
Explore how leading teams are using trusted data and targeted AI to design, plan, and execute trials with the confidence today’s science requires.
Learning outcomes:
– Understand what’s driving trial complexity
– Design protocols with confidence using real data + AI
– Select sites based on holistic drivers of outcomes; access, experience and past performance
– Rethink patient recruitment as the critical success factor
– Align with evolving regulatory expectations (ICH GCP E6 R3)

CAR-T for Relapsed/Refractory AML: From Discovery to First-in-Human Active Phase 1 Evaluation
2026-08-20 11:00 - 12:00 | Online webinar
Join Dr. Marco Davila to explore a novel anti-CD83 CAR-T design for relapsed/refractory AML that overcomes myelosuppression barriers. Register for the live session.
Developing effective Chimeric Antigen Receptor (CAR) T-cell therapies for Acute Myeloid Leukemia (AML) remains one of the most formidable frontiers in cellular immunotherapy. Unlike lymphoid malignancies where lineage-specific targets like CD19 or BCMA offer a clear therapeutic window, AML presents a severe biological bottleneck. The vast majority of well-characterized myeloid antigens (such as CD33 or CD123) are shared with healthy hematopoietic stem and progenitor cells (HSPCs). Consequently, conventional CAR-T approaches frequently induce prolonged, life-threatening myelosuppression and bone marrow aplasia severely limiting their clinical utility. This webinar by Dr. Marco Davila will explore a paradigm-shifting strategy developed at Roswell Park Comprehensive Cancer Center that addresses this exact barrier: a novel CAR-T design targeting the CD83 antigen.
Our discussion will center on the unique biology of CD83, a protein highly expressed on malignant AML blasts but distinctively regulated in healthy tissues, offering a pathway to selectively suppress leukemia cells while sparing critical progenitor stem cells. Moving from bench to bedside, we will detail the rigorous process development and GMP manufacturing frameworks involved in generating this CAR-T cell therapy to be tested in clinic. Finally, we will share insights into the initiation and objectives of the first-of-its-kind, active Phase 1 clinical trial evaluating autologous anti-CD83 CAR-T cell infusions in patients with relapsed or refractory AML. Join us to discover how this dual-action architecture reshapes safety, efficacy, and translation benchmarks in the myeloid cell therapy space.

FDA Engagement Strategies And Best Practices Amid Agency Changes
2026-08-20 11:00 - 12:00 | Online webinar
How can life sciences companies developing new medicines engage the FDA successfully during a period of rapid changes in agency personnel and policies?
Should companies adjust their agency communication strategies or ask new questions during meetings? Our deeply experienced panelists will discuss key changes at the FDA, how companies can get the most out of agency interactions, and strategies to lower risks and avoid regulatory surprises.
Register for free today and secure your spot for this important virtual event.

Outsourced Pharma Capabilities Update August 2026: Oral Solid Dose Formulation
2026-08-18 13:00 - 14:00 | Online webinar
Oral solid dose programs can run into costly scale-up challenges when early formulation and process decisions aren’t built for long-term manufacturability.
Join leading CDMO experts on August 18 at 1:00 PM ET to explore how excipient selection, granulation strategy, particle engineering, and process design can impact tech transfer, validation, and commercial manufacturing.
Register now to gain practical insights for evaluating CDMO capabilities, identifying scale-up risks earlier, and making more informed partner selection decisions.

Outsourced Pharma Capabilities Update August 2026: Nanoparticles
2026-08-18 11:00 - 12:00 | Online webinar
Nanoparticle programs can stall when early formulation choices fail to hold up through scale-up, tech transfer, and manufacturing.
Join leading CDMO experts on August 18 at 11:00 AM ET to learn how decisions around lipid or polymer selection, particle engineering, process design, and manufacturability can impact downstream success.
Register now to gain practical insights that will help you evaluate CDMO approaches, ask sharper formulation questions, and reduce risk before nanoparticle challenges become costly development setbacks.

The Future of Cell Culture Media Development: Predictive Modeling and AI
2026-08-18 11:00 - 12:00 | Online webinar
As biologics developers work to improve productivity, reduce development timelines, and manage manufacturing costs, traditional media optimization approaches can become increasingly resource intensive. Predictive modeling is emerging as a complementary approach that can help integrate biological knowledge, process data, and artificial intelligence (AI) to support more efficient media development.
In this webinar, Thermo Fisher Scientific specialists discuss how predictive modeling and AI are being applied to cell culture media development. Learn how computational modeling can help identify promising formulation strategies, focus experimental efforts, and support more informed development decisions while maintaining the critical role of scientific expertise.
In this session, you will learn about:
~ The emerging role of predictive modeling in cell culture media development
~ How AI can help support formulation optimization
~ The value of integrating biological, analytical, and process data
~ How predictive modeling and scientific expertise can work together to inform development decisions
Key topics include:
~ Challenges with traditional media optimization approaches
~ AI-guided formulation design and in silico modeling
~ Human expertise in predictive model development and validation
~ Cross-functional collaboration in AI-enabled media development
~ Predictive modeling in biologics development
Discover how predictive modeling and AI are helping shape the future of cell culture media development by supporting more informed, data-driven approaches to media optimization.

The Matrix One West Coast MedTech Forum
2026-08-18 - 2026-08-27 | California (multiple locations), CA, United States
The Matrix One West Coast MedTech Forum is a free series of expert roundtables, educational sessions and networking events taking place across California from 18 to 27 August 2026. Designed for professionals throughout the MedTech and life sciences community, the programme brings together regulatory affairs, quality, engineering, product, digital health and business leaders.
Attendees will explore some of the most important issues shaping medical device development, including practical applications of AI, regulatory submissions, design control, audit readiness, quality management, cloud connectivity, cybersecurity and compliant product development. Events will take place across San Francisco, Palo Alto, Redwood City, Los Angeles, Irvine and San Diego, featuring insights from industry experts, legal specialists, former FDA professionals and local MedTech leaders, alongside valuable opportunities to connect with peers.

From Data to Decisions: AI and Multi-Omics for Cell Culture Development
2026-08-13 13:00 - 14:00 | Online webinar
As biologics developers work to improve productivity, maintain product quality, and accelerate development timelines, traditional optimization approaches can sometimes reach a point of diminishing returns. While cell culture processes generate vast amounts of biological and process data, extracting actionable insights from that information remains a significant challenge.
In this webinar, Thermo Fisher Scientific specialists discuss how the integration of multi-omics data, artificial intelligence (AI), and deep cell culture expertise can help uncover the biological mechanisms driving process performance. Learn how AI-enabled analytics can support more informed decision-making, identify optimization opportunities, and accelerate media and process development.
In this session, you will learn about:
~ The role of multi-omics in understanding cell culture performance
~ How AI is helping uncover biological drivers of productivity and quality
~ Emerging applications of predictive modeling in media and process development
~ New approaches to turning complex biological data into actionable insights
Key topics include:
~ Case study: using AI and metabolomics to overcome optimization plateaus
~ Multi-omics approaches in cell culture development
~ AI-enabled data integration and pattern recognition
~ Understanding productivity and product quality trade-offs
~ From biological data to development decisions
Discover how AI and multi-omics are helping developers move beyond descriptive analytics toward more predictive, mechanism-based approaches to cell culture optimization.

When Unexpected Particles Threaten Your Biologic
2026-08-13 11:00 - 12:00 | Online webinar
Unexpected particle findings can raise critical questions about product quality, patient safety, and regulatory compliance.
Join KBI Biopharma’s experts to learn how clinical in-use studies and advanced particle forensics can help identify particle sources, assess risk, and build regulator-ready evidence for confident decision-making.
Register now to discover practical strategies for accelerating investigations, supporting development timelines, and responding effectively when unexpected particles threaten your biologic.

Commercial Readiness Solutions
2026-08-13 10:00 - 12:00 | Online webinar
The journey from a successful lab result to a reliable, GMP-compliant product is rarely a straight line. It’s a transition filled with technical hurdles, regulatory pressure, and the constant challenge of scaling without compromise.
We created the Commercial Readiness Solutions session to help you navigate this transition. This virtual event is designed to be highly practical – moving past high-level theory to focus on the specific tools and partnerships needed to solve the real-world bottlenecks in your production lifecycle.
Join us to evaluate the solutions and technologies essential for a sustainable commercial platform, including:
GMP Execution & Inspection Readiness: Building the protocols and confidence to meet global regulatory standards.
Manufacturing Scale-up: Leveraging closed-system automation to reduce manual risk and variability.
Contamination Control: Implementing advanced strategies to ensure sterility and product safety at scale.
QC & Release Testing: Optimizing testing strategies to accelerate the path from the facility to the patient.
Validation & Data Integrity: Ensuring your process documentation is robust, transparent, and compliant.
Digital Infrastructure: Integrating eQMS, MES, and LIMS for a seamless, paperless manufacturing environment.
Practical Insights, Not Just Presentations. Through solution-focused sessions and real-world case studies, this event will highlight the supplier capabilities and technologies that reduce risk and accelerate your timelines. Our goal is to show you how to strengthen your operational resilience – maintaining the highest quality standards without sacrificing the throughput you need to stay competitive.
Move Forward with Confidence. Whether you are preparing for your next inspection, refining your control strategy, or building a repeatable platform for the global market, we are here to connect you with the right expertise. Join us to find the tools and insights you need to move confidently from development to commercial success – bringing life-changing therapies to more patients, faster.

BVS and BioMed Realty's Biotech Community Event in SSF
2026-08-12 16:00 - 18:30 | South San Francisco, CA, CA, 94080, United States
Join Us for the BVS and BioMed Realty Biotech Community Event!
Mark your calendars for a great opportunity to connect with industry leaders, explore innovative products, and mingle with fellow professionals in the biotech community.
The vendor fair is held at The Forum, in the same building as Amgen and next to Genentech, right in the heart of the large pharma/biotechs in South San Francisco.
✨ What to Expect:
Vendor Exhibit: Discover a diverse range of exhibitors showcasing cutting-edge technology and services in the biotech space.
Networking Opportunities: Engage with fellow industry experts, forge new connections, and exchange ideas that could shape the future of biotech.
Appetizers & Drinks: Enjoy delicious refreshments as you network and explore the vendor exhibits.
We welcome the entire Bay Area Biotech Community to join us for this exciting event! This is a wonderful chance for everyone to come together, share insights, and celebrate the vibrant biotech landscape in our region.
Admission Details:
FREE for life science job-related employees (including researchers, scientists, purchasing, clinical, manufacturing, non-sales/bus dev positions etc.) from life science companies and research institutes.
$200 fee for product and service providers who sell to the life science community (e.g. BVS suppliers, business development/sales, marketing, lawyers, consultants), which includes access to the event but does not include an exhibitor table. Exhibitor tables can be purchased separately.
For exhibitor tables, please visit our website and register at: https://bvsconnection.com/events
Please feel free to invite others in the community that could benefit from attending.
We look forward to seeing you there!

IRB in Action: A Live Mock Board Review
2026-08-12 13:00 - 14:00 | Online webinar
Join Univo IRB for a unique educational webinar that takes attendees inside the IRB decision-making process through a live mock board review. Using a fictional agenda item based on real clinical and ethical challenges, experienced IRB members will evaluate key protocol considerations including risk-benefit assessment, informed consent, participant protections, recruitment strategies, and regulatory compliance. This session is designed to help sponsors, CROs, sites, and clinical research professionals better understand how IRBs review protocols and make decisions that support ethical, compliant research.

Gene Therapy Solutions
2026-08-12 10:00 - 12:00 | Online webinar
Cell & Gene Tech Expo offers a live virtual experience designed to empower industry professionals in sourcing best-fit solutions for their cell and gene therapy manufacturing needs. Through this series of digital sessions, attendees will have the chance to explore the newest equipment and solutions offered by our presenters, aimed at addressing the current challenges within the cell and gene therapy manufacturing process. This interactive online experience ensures convenience and accessibility, fostering an environment of learning and innovation for all participants.
The attendees of the Gene Therapy Equipment session will have the chance to explore the newest equipment and solutions offered by our presenting suppliers.
What can you expect? Short, digital presentations with live interaction. You will have the opportunity to ask questions to better understand if suppliers can meet your needs – all from the convenience of your computer!

Cell Therapy Solutions
2026-08-11 10:00 - 12:00 | Online webinar

The Bioprocessing Summit 2026
2026-08-10 - 2026-08-13 | Boston, MA, 02210, United States
Elevate your expertise, embrace innovation, and join the global leaders who are transforming the future of bioprocessing.
Now in its 18th year, the Bioprocessing Summit unites a global community of scientists, engineers, and executives driving innovation and digitalization across process development, scale-up, quality, and analytics for biologics, antibodies, cell and gene, RNA, and oligonucleotide therapies.
Explore how technology, data, and AI are reshaping every stage of the bioprocessing journey — Transforming Bioprocessing for the Digital Age

Built for Growth: Engineering Flexible and Scalable Bioprocessing Strategies
2026-08-06 11:00 - 12:00 | Online webinar
As biopharmaceutical manufacturing becomes increasingly global, organizations face growing challenges in balancing flexibility, standardization, and scalability. CDMOs must accommodate sponsor-specific requirements, manufacturers must transfer processes across geographically dispersed facilities, and growing programs require equipment platforms that can scale without introducing unnecessary risk or complexity.
Successfully navigating these challenges requires more than equipment; it requires a partner who can help define standards, align stakeholders, and anticipate future needs before they become obstacles.
In this webinar, we will explore how a collaborative, engineering-first approach can help biopharmaceutical manufacturers build more resilient and adaptable manufacturing strategies. Through real-world examples, attendees will learn how organizations have addressed sponsor-driven variability in single-use filtration, established global design standards across multiple manufacturing sites, and developed scalable platform strategies that support seamless progression from clinical to commercial manufacturing.
Join us to discover how thoughtful system design, strategic planning, and trusted partnerships can help future-proof manufacturing operations while reducing risk, simplifying technology transfer, and supporting long-term growth.
Key Objectives:
~ Identify key strategies for balancing flexibility, standardization, and scalability in modern biopharmaceutical manufacturing
~ Understand how collaborative engineering and trusted partnerships can simplify technology transfer, align stakeholders, and reduce operational risk
~ Explore real-world approaches to designing manufacturing platforms that support sponsor variability today while enabling seamless growth from clinical to commercial production

Outsourced Pharma Capabilities Update: Cell Line Development
2026-08-05 11:00 - 12:00 | Online webinar
In this virtual event, leading CDMOs will share how host selection, vector design, and clone screening strategies influence manufacturability from early development through commercialization.
Join us to learn what to evaluate early, how to reduce downstream risk, and how to make more informed cell line development decisions.

Charting a Direct Pathway from Academia To CDMOs
2026-08-04 11:00 - 12:00 | Online webinar
Moving promising research from the university lab to the CDMO suite requires more than breakthrough science—it requires the right documentation, development strategy, and manufacturing readiness.
In this Outsourced Pharma Live discussion, industry experts explore how academic innovators and CDMOs can better align earlier, build stronger technical packages, and create a smoother path to outsourced development and manufacturing.
Watch the discussion to learn how to make academic programs more CDMO-ready and accelerate the journey from discovery to execution.

Ensuring Successful Technology Transfer In ADC Development
2026-08-04 11:00 - 12:00 | Online webinar
Technology transfers can introduce risk and create knowledge gaps at every stage of development, whether it’s moving a process from development to manufacturing, transferring methods between analytical labs, or onboarding a new CDMO partner. This is especially true in the development of antibody-drug conjugates (ADC), where the complexity of conjugation processes, analytical characterization, and specialized manufacturing expertise is often distributed across multiple CDMO partners.
Join Bioprocess Online’s Tyler Menichiello for an interactive panel discussion with Sourav Kundu, Ph.D., senior vice president of development and manufacturing at NextCure, and Will Olughu, Ph.D., global CMC lead and senior principal scientist at Ipsen, as they explore practical ways to navigate the transfer of process and analytical knowledge in ADC development to reduce risk and avoid delays.

Breaking the Bottleneck: How Modular Workflows Are Redefining CAR T Manufacturing Performance, Flexibility, and Scalability
2026-07-30 11:00 - 12:00 | Online webinar
As cell therapies advance toward commercial-scale manufacturing, developers can face increasing pressure to balance performance, scalability, and process flexibility. Flexible modular workflows are emerging as a powerful approach for scalable cell therapy manufacturing, enabling enhanced process control, workflow adaptability, and operational efficiency while maintaining consistency across the manufacturing pipeline. These advantages can be particularly valuable in environments where evolving process requirements may challenge more fixed manufacturing approaches.
In this webinar, we will explore how modular Gibco™ CTS™ workflows compare to an integrated system across critical CAR T manufacturing quality attributes, including transduction efficiency, T cell activation, expansion, and phenotype preservation. Data demonstrate that modular workflows can achieve high transduction efficiency (up to ~80% by day 8), increased CAR+ T cell yields, and enhanced enrichment of stem cell–like memory (TSCM) populations, which can be key factors associated with improved therapeutic potential.
We will also highlight how flexibility in workflow design enables parallel processing, reduced instrument lock times, and improved operational efficiency, without compromising cell quality metrics such as purity and isolation efficiency. Attendees will gain practical insights into how modular strategies can future-proof manufacturing processes and support both early development and commercial-scale production.
Key Learning Objectives
Understand how modular workflows impact critical CAR T manufacturing attributes, including transduction efficiency, expansion, and T cell phenotype
Evaluate the trade-offs between integrated and modular systems in terms of scalability, flexibility, and operational efficiency
Learn how flexible workflow design can enable parallel processing, reduce bottlenecks, and support evolving process requirements

Outsourced Pharma Capabilities Update July 2026: Large Molecule
2026-07-29 13:00 - 14:00 | Online webinar
Explore the latest large molecule manufacturing capabilities from leading CDMOs in this informative webinar.
Learn about advances in cell line development, fermentation, purification, process optimization, and scale-up, while gaining insight into available capacity, facility locations, and timelines.
Whether you’re evaluating manufacturing partners or planning future biologics production, this session offers a practical overview to help you identify the right CDMO for your program.

Outsourced Pharma Capabilities Update July 2026: Fill/Finish
2026-07-29 11:00 - 12:00 | Online webinar
Looking for fill-finish manufacturing capacity? This webinar brings together leading CDMOs to showcase their latest sterile filling, lyophilization, and advanced packaging capabilities, along with current facility availability and timelines.
Gain valuable insights into quality, regulatory compliance, and manufacturing options to help identify the right partner for your biopharmaceutical development and commercialization needs.
